241 related articles for article (PubMed ID: 23208507)
1. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
Yang WC; Shih HM
Oncogene; 2013 Oct; 32(43):5167-75. PubMed ID: 23208507
[TBL] [Abstract][Full Text] [Related]
2. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
3. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
4. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
5. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
Dos Santos GA; Kats L; Pandolfi PP
J Exp Med; 2013 Dec; 210(13):2793-802. PubMed ID: 24344243
[TBL] [Abstract][Full Text] [Related]
6. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of genome-wide PLZF/RARA target genes.
Spicuglia S; Vincent-Fabert C; Benoukraf T; Tibéri G; Saurin AJ; Zacarias-Cabeza J; Grimwade D; Mills K; Calmels B; Bertucci F; Sieweke M; Ferrier P; Duprez E
PLoS One; 2011; 6(9):e24176. PubMed ID: 21949697
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
9. Two critical hits for promyelocytic leukemia.
He LZ; Bhaumik M; Tribioli C; Rego EM; Ivins S; Zelent A; Pandolfi PP
Mol Cell; 2000 Nov; 6(5):1131-41. PubMed ID: 11106752
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.
Hussain L; Maimaitiyiming Y; Islam K; Naranmandura H
Semin Oncol; 2019 Apr; 46(2):133-144. PubMed ID: 31126665
[TBL] [Abstract][Full Text] [Related]
11. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
Beez S; Demmer P; Puccetti E
PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790
[TBL] [Abstract][Full Text] [Related]
12. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
13. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements.
Sainty D; Liso V; Cantù-Rajnoldi A; Head D; Mozziconacci MJ; Arnoulet C; Benattar L; Fenu S; Mancini M; Duchayne E; Mahon FX; Gutierrez N; Birg F; Biondi A; Grimwade D; Lafage-Pochitaloff M; Hagemeijer A; Flandrin G; ; ; ;
Blood; 2000 Aug; 96(4):1287-96. PubMed ID: 10942370
[TBL] [Abstract][Full Text] [Related]
14. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Jo S; Lee YL; Kim S; Lee H; Chung H
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
16. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
[TBL] [Abstract][Full Text] [Related]
17. Recurrent
Osumi T; Tsujimoto SI; Tamura M; Uchiyama M; Nakabayashi K; Okamura K; Yoshida M; Tomizawa D; Watanabe A; Takahashi H; Hori T; Yamamoto S; Hamamoto K; Migita M; Ogata-Kawata H; Uchiyama T; Kizawa H; Ueno-Yokohata H; Shirai R; Seki M; Ohki K; Takita J; Inukai T; Ogawa S; Kitamura T; Matsumoto K; Hata K; Kiyokawa N; Goyama S; Kato M
Cancer Res; 2018 Aug; 78(16):4452-4458. PubMed ID: 29921692
[TBL] [Abstract][Full Text] [Related]
18. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
19. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
20. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
